logo

Alnylam Pharmaceuticals Inc. (ALNY)



Trade ALNY now with
  Date
  Headline
10/22/2020 10:14:41 AM Alnylam Presents Positive Results From Phase 3 Study In Pediatric Patients With Primary Hyperoxaluria Type 1
10/16/2020 6:03:42 AM Alnylam Gets Positive CHMP Opinion For OXLUMO For Primary Hyperoxaluria Type 1 In All Age Groups
9/30/2020 7:07:08 AM Alnylam Reports Positive Topline Results From ILLUMINATE-B Phase 3 Study Of Lumasiran
8/17/2020 7:34:16 AM Blackstone And Alnylam Close $150 Mln R&D Financing To Advance RNAi Therapeutics For Cardiovascular Disease
8/6/2020 8:09:44 AM Alnylam Pharmaceuticals Inc. (ALNY) Has Raised Its FY20 Revenue Estimate To $280 - $300 Mln From $270 - $300 Mln
8/6/2020 8:04:25 AM Alnylam Pharma Q2 Non-GAAP Loss/shr Narrows To $1.67 From $1.83 Prior Year
8/6/2020 7:34:49 AM Alnylam Says Barry Greene, President, Decided To Leave Company At Q3 End
8/3/2020 7:35:32 AM Alnylam Pharma Submits CTA Application For ALN-HSD For The Treatment Of Nonalcoholic Steatohepatitis
6/30/2020 9:07:16 AM Alnylam Presents New Data From Open-label Extension Period Of ENVISION Phase 3 Study